CRISPR THERAPEUTICS AG's ticker is CRSP and the CUSIP is H17182108. A total of 310 filers reported holding CRISPR THERAPEUTICS AG in Q3 2020. The put-call ratio across all filers is 1.02 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $35,177 | -19.2% | 775 | 0.0% | 0.00% | 0.0% |
| Q2 2023 | $43,509 | +24.1% | 775 | 0.0% | 0.00% | 0.0% |
| Q1 2023 | $35,053 | +11.3% | 775 | 0.0% | 0.00% | +100.0% |
| Q4 2022 | $31,504 | -19.2% | 775 | +31.1% | 0.00% | -50.0% |
| Q3 2022 | $39,000 | +8.3% | 591 | 0.0% | 0.00% | 0.0% |
| Q2 2022 | $36,000 | -2.7% | 591 | 0.0% | 0.00% | +100.0% |
| Q1 2022 | $37,000 | -58.0% | 591 | -49.2% | 0.00% | -50.0% |
| Q4 2021 | $88,000 | -19.3% | 1,164 | +18.7% | 0.00% | -33.3% |
| Q3 2021 | $109,000 | -31.0% | 981 | 0.0% | 0.00% | -25.0% |
| Q2 2021 | $158,000 | +32.8% | 981 | 0.0% | 0.00% | 0.0% |
| Q1 2021 | $119,000 | +15.5% | 981 | +46.2% | 0.00% | +33.3% |
| Q4 2020 | $103,000 | +80.7% | 671 | -1.5% | 0.00% | +50.0% |
| Q3 2020 | $57,000 | +62.9% | 681 | +44.0% | 0.00% | +100.0% |
| Q2 2020 | $35,000 | +218.2% | 473 | +81.9% | 0.00% | 0.0% |
| Q1 2020 | $11,000 | – | 260 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Versant Venture Management, LLC | 498,558 | $27,989,046 | 33.20% |
| Gilfoyle Management LLC | 100 | $4,842 | 15.90% |
| NEA Management Company, LLC | 1,587,854 | $89,142,124 | 6.80% |
| ARK Investment Management | 7,338,447 | $411,980,394 | 2.73% |
| Nikko Asset Management Americas, Inc. | 3,533,357 | $198,327,328 | 2.09% |
| Del-Sette Capital Management, LLC | 33,661 | $1,889,729 | 1.79% |
| Ikarian Capital, LLC | 200,000 | $11,228,000 | 1.79% |
| Ikarian Capital, LLC | 200,000 | $11,228,000 | 1.79% |
| Merlin Capital, Inc | 8,802 | $494,144 | 1.67% |
| Green Alpha Advisors, LLC | 34,373 | $1,929,700 | 1.27% |